Ning Ling, Ma Hui, Jiang Zhuyun, Chen Lu, Li Li, Chen Qianfeng, Qi Hongyi
Southwest University, Chongqing, China.
Southwest University, Chongqing, China
Integr Cancer Ther. 2016 Jun;15(2):216-25. doi: 10.1177/1534735416642865. Epub 2016 Apr 28.
Curcumolhas been reported to possess antitumor activity. However, its effect and mechanisms against tumor metastasis are still unclear. This study is to investigate the inhibitory effect of curcumol on breast cancer cell metastasis and elucidate the underlying molecular mechanisms. Our results showed that noncytotoxicity was caused by curcumol within 10 to 40 µg/mL in MDA-MB-231 and 4T1 cells for 24 hours, whereas sustained treatment with curcumol for 14 days significantly suppressed the clonogenic activity of cells. Importantly, curcumol at noncytotoxic concentrations suppressed the migration ability of both MDA-MB-231 and 4T1 cells. Moreover, curcumol suppressed the migration and invasion of MDA-MB-231 cells in the Boyden chamber migration and invasion assay and inhibited the adhesion of MDA-MB-231 cells onto the matrigel. Further investigations revealed that curcumol decreased the enzyme activity and protein expression of matrix metalloproteinase (MMP-9) in MDA-MB-231 cells. Moreover, curcumol inhibited the activation of c-Jun N-terminal kinase (JNK) 1/2 and Akt (Ser473). Meanwhile, it also inhibited the nuclear translocation and transcriptional activity of nuclear factor κB (NF-κB). Furthermore, JNK inhibitor SP600125 and Akt (Ser473) inhibitor LY294002 enhanced the inhibition of curcumol on NF-κB p65 nuclear translocation. Finally, supplementation with SP600125, LY294002, or NF-κB inhibitor Ammonium pyrrolidinedithiocarbamate (PDTC) significantly enhanced the inhibitory effect of curcumol on MMP-9 expression and cell migration, invasion, and adhesion in MDA-MB-231 cells. Our findings provide evidence for the suppression of breast cancer cell metastasis by curcumol and suggest that the inhibition of MMP-9 via JNK1/2 and Akt (Ser473)-dependent NF-κB signaling pathways may be the underlying mechanisms.
据报道,莪术醇具有抗肿瘤活性。然而,其对肿瘤转移的作用及机制仍不清楚。本研究旨在探讨莪术醇对乳腺癌细胞转移的抑制作用,并阐明其潜在的分子机制。我们的结果表明,在MDA-MB-231和4T1细胞中,10至40μg/mL的莪术醇作用24小时不会引起细胞毒性,而莪术醇持续处理14天则显著抑制细胞的克隆形成活性。重要的是,非细胞毒性浓度的莪术醇可抑制MDA-MB-231和4T1细胞的迁移能力。此外,在Boyden小室迁移和侵袭试验中,莪术醇抑制了MDA-MB-231细胞的迁移和侵袭,并抑制了MDA-MB-231细胞与基质胶的黏附。进一步研究发现,莪术醇降低了MDA-MB-231细胞中基质金属蛋白酶(MMP-9)的酶活性和蛋白表达。此外,莪术醇抑制了c-Jun氨基末端激酶(JNK)1/2和Akt(Ser473)的激活。同时,它还抑制了核因子κB(NF-κB)的核转位和转录活性。此外,JNK抑制剂SP600125和Akt(Ser473)抑制剂LY294002增强了莪术醇对NF-κB p65核转位的抑制作用。最后,补充SP600125、LY294002或NF-κB抑制剂吡咯烷二硫代氨基甲酸铵(PDTC)显著增强了莪术醇对MDA-MB-231细胞中MMP-9表达及细胞迁移、侵袭和黏附的抑制作用。我们的研究结果为莪术醇抑制乳腺癌细胞转移提供了证据,并表明通过JNK1/2和Akt(Ser473)依赖的NF-κB信号通路抑制MMP-9可能是其潜在机制。